NCT04885660View on ClinicalTrials.gov

Bioequivalence Evaluation of Two Fixed-dose Combination of Lisinopril 10mg/Levamlodipine Besylate 5mg in Healthy Chinese Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

October 12, 2018

Primary Completion Date

November 15, 2018

Study Completion Date

November 20, 2019

Conditions
Therapeutic Equivalency
Interventions
DRUG

compound lisinopril tablet

The subjects randomly received single oral administration of compound lisinopril tablet(Lisinopril 10mg/Levamlodipine besylate 5mg)

DRUG

compound lisinopril tablet(Lisonorm®)

The subjects randomly received single oral administration of compound lisinopril tablet(Lisonorm®)

Trial Locations (1)

266003

The Affiliated Hospital of Qingdao University, Qingdao

All Listed Sponsors
lead

The Affiliated Hospital of Qingdao University

OTHER

NCT04885660 - Bioequivalence Evaluation of Two Fixed-dose Combination of Lisinopril 10mg/Levamlodipine Besylate 5mg in Healthy Chinese Subjects | Biotech Hunter | Biotech Hunter